The immune activation of CLL cells with subsequent upregulation of costimulatory molecules, such as, CD40, CD80 and CD86, might be responsible for Tumor Flare observed in CLL patients treated with lenalidomide [6]. This evidence concerns the gene CD80 and B-cell chronic lymphocytic leukemia.